FEMY
FEMASYS INC
$4.18
-12.55%
$12.6M
No data for this timeframe.
Vol
Market Cap$12.6M
Cap SizeNano Cap
Reddit Sentiment60° Warm
SEC Reports5
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001339005·Prev Close $4.78
Recent Activity
Jun 5, 2026
short_volume
Short Volume: FEMY — 58.9% short (1.0M / 1.7M)
Short: 996,787 | Exempt: 225,999 | TRF Vol: 1,692,092 | Short Ratio: 58.9% | Off-exchange volume (da
Jun 4, 2026
SEC
Femasys announced a 1-for-20 reverse stock split effective June 5, 2026, with split-adjusted trading beginning June 8, 2
8-K — Impact 4/10
May 13, 2026
SEC
Femasys Inc. filed an 8-K on May 13, 2026, posting an updated corporate slide presentation (Exhibit 99.1) on its website
8-K — Impact 3/10
May 8, 2026
SEC
Femasys reported Q1 2026 revenue of $424,889 (+24.5% YoY) driven by FemBloc sales, with a net income of $846,100 due to
8-K — Impact 4/10
Mar 30, 2026
Insider
Canning John Charles was granted 150,000 shares
Chief Operating Officer
Mar 19, 2026
Insider
Eichenbaum Kenneth D. was granted 102,366 shares
Director
Mar 19, 2026
Insider
Elefant Dov was granted 34,122 shares
Chief Financial Officer
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$63.33 (Mar 2026)
Current $4.18
Low $30.00
Median $30.00
High $130.00
0 analysts
$30.00
$130.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 3, 2026 | Lake Street | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.40 ▲ +22.2% | $-1.60 — $-1.20 | 56% YoY | 2 |
| Next Q | $-1.50 ▲ +21.1% | $-1.60 — $-1.40 | 25% YoY | 2 |
| Current FY | $-5.00 ▲ +31.5% | $-6.00 — $-4.00 | 47% YoY | 2 |
| Next FY | $-5.80 ▲ +18.3% | $-6.20 — $-5.40 | -16% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
Femasys announced a 1-for-20 reverse stock split effective June 5, 2026, with split-adjusted trading beginning June 8, 2
Jun 4, 2026
NEUTRAL
8-K
3/10
Femasys Inc. filed an 8-K on May 13, 2026, posting an updated corporate slide presentation (Exhibit 99.1) on its website
May 13, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 30, 2026 | Canning John | A | $0.00 |
| Mar 19, 2026 | Eichenbaum Kenneth | A | $0.00 |
| Mar 19, 2026 | Elefant Dov | A | $0.00 |
| Mar 19, 2026 | Larsen Charles | A | $0.00 |
| Mar 19, 2026 | Lee-Sepsick Kathy | A | $0.00 |
Reddit Sentiment
60°▼
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
6 unique insiders with 9 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Canning John Charles | Chief Operating Officer | AWARD | 150,000 | — | — |
| Mar 19, 2026 | Eichenbaum Kenneth D. | Director | AWARD | 102,366 | — | — |
| Mar 19, 2026 | Elefant Dov | Chief Financial Officer | AWARD | 34,122 | — | — |
| Mar 19, 2026 | Larsen Charles | Director | AWARD | 34,122 | — | — |
| Mar 19, 2026 | Lee-Sepsick Kathy | Chief Executive Officer | AWARD | 68,244 | — | — |
| Mar 18, 2026 | Eichenbaum Kenneth D. | Director | AWARD | 35,200 | — | — |
| Feb 19, 2026 | Elefant Dov | Chief Financial Officer | AWARD | 173,000 | — | — |
| Feb 19, 2026 | Lee-Sepsick Kathy | Chief Executive Officer | AWARD | 447,000 | — | — |
| Feb 2, 2026 | Sipos Jeremy Alexander | Chief Technology Officer | AWARD | 80,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.2/10.
NEUTRAL
8-K
4/10
Femasys announced a 1-for-20 reverse stock split effective June 5, 2026, with split-adjusted trading
Jun 4, 2026
NEUTRAL
8-K
3/10
Femasys Inc. filed an 8-K on May 13, 2026, posting an updated corporate slide presentation (Exhibit
May 13, 2026
NEUTRAL
8-K
4/10
Femasys reported Q1 2026 revenue of $424,889 (+24.5% YoY) driven by FemBloc sales, with a net income
May 8, 2026
NEUTRAL
DEFA14A
2/10
Femasys filed definitive additional proxy materials for its 2026 annual meeting, including proposals
Apr 30, 2026
BULLISH
8-K
8/10
Femasys reported full-year 2025 revenue of $2.29M, up 40.8% YoY, with a net loss per share of $0.47,
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Mar 2026): 89% buy across 9 analysts — 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$63.33 mean target (Mar 2026)
$30.00 Low
$130.00 High
| Metric | Value |
|---|---|
| Current Price | $4.18 |
| Target Low | $30.00 |
| Target Mean | $63.33 |
| Target Median | $30.00 |
| Target High | $130.00 |
| # Analysts | 0 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.40 | $-1.60 | $-1.20 | 56.3% | +22.2% | 1↑ 0↓ | $0.0B | 78.5% | 2 |
| Next Q 2026-09-30 |
$-1.50 | $-1.60 | $-1.40 | 25.0% | +21.1% | 1↑ 0↓ | $0.0B | 50.8% | 2 |
| Current FY 2026-12-31 |
$-5.00 | $-6.00 | $-4.00 | 46.8% | +31.5% | — | $0.0B | 64.2% | 2 |
| Next FY 2027-12-31 |
$-5.80 | $-6.20 | $-5.40 | -16.0% | +18.3% | 1↑ 0↓ | $0.0B | 165.6% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.400 | |
| 7d ago | $-1.800 | +0.400 |
| 30d ago | $-1.800 | +0.400 |
| 60d ago | $-1.900 | +0.500 |
| 90d ago | $0.000 | -1.400 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 3, 2026 | Lake Street | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
11 mentions
6 bullish
3 bearish
11 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 29, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 29, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 17, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 17, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
FEMY Shareholders Approve Reverse Split
▲ 1
💬 0
⚡ 0.5
NUAI, CING, SLS or FEMY…
▲ 1
💬 1
⚡ 0.5
FEMY DD into Earnings ⭐️
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: FEMY — 58.9% short (1.0M / 1.7M)
Short: 996,787 | Exempt: 225,999 | TRF Vol: 1,692,092 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: FEMY — 56.2% short (0.3M / 0.5M)
Short: 288,398 | Exempt: 0 | TRF Vol: 513,593 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: FEMY — 63.9% short (2.7M / 4.3M)
Short: 2,735,200 | Exempt: 54,962 | TRF Vol: 4,283,026 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- <pre>-- New catheter complements FemVue® and supports s
May 8, 2026
earnings
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat pati
May 7, 2026
earnings_calendar
FEMY Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
earnings_calendar
FEMY Q1 2026 Earnings Scheduled — 2026-05-06
Mar 31, 2026
earnings
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- <pre>-- Enrollment underway in
Mar 26, 2026
earnings_calendar
FEMY Q4 2025 Earnings After Market Close — 2026-03-26